Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis

William G Herrington, Zhaojing J Che, Rebecca Sardell, Alistair J Roddick, Parminder K Judge, Christoph Wanner, Sibylle J Hauske, Stefan Anker, Javed Butler, Gerasimos Filippatos, Milton Packer, Faiez Zannad, Dominik Steubl, Martina Brueckmann, Jennifer B Green, Jonathan R Emberson, Martin J Landray, Colin Baigent, Richard Haynes, Natalie Staplin

Open source

DOI: 10.1016/s2213-8587(25)00222-0
Published: 2025-12
Container: The Lancet Diabetes & Endocrinology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2213-8587-25-00222-0,
  title = {Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis},
  author = {William G Herrington and Zhaojing J Che and Rebecca Sardell and Alistair J Roddick and Parminder K Judge and Christoph Wanner and Sibylle J Hauske and Stefan Anker and Javed Butler and Gerasimos Filippatos and Milton Packer and Faiez Zannad and Dominik Steubl and Martina Brueckmann and Jennifer B Green and Jonathan R Emberson and Martin J Landray and Colin Baigent and Richard Haynes and Natalie Staplin},
  year = {2025},
  journal = {The Lancet Diabetes \&amp; Endocrinology},
  doi = {10.1016/s2213-8587(25)00222-0},
  url = {https://doi.org/10.1016/s2213-8587(25)00222-0}
}

RIS

TY  - JOUR
TI  - Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis
AU  - William G Herrington
AU  - Zhaojing J Che
AU  - Rebecca Sardell
AU  - Alistair J Roddick
AU  - Parminder K Judge
AU  - Christoph Wanner
AU  - Sibylle J Hauske
AU  - Stefan Anker
AU  - Javed Butler
AU  - Gerasimos Filippatos
AU  - Milton Packer
AU  - Faiez Zannad
AU  - Dominik Steubl
AU  - Martina Brueckmann
AU  - Jennifer B Green
AU  - Jonathan R Emberson
AU  - Martin J Landray
AU  - Colin Baigent
AU  - Richard Haynes
AU  - Natalie Staplin
PY  - 2025
JO  - The Lancet Diabetes &amp; Endocrinology
DO  - 10.1016/s2213-8587(25)00222-0
UR  - https://doi.org/10.1016/s2213-8587(25)00222-0
ER  -

APA

Herrington, W. G., Che, Z. J., Sardell, R., Roddick, A. J., Judge, P. K., Wanner, C., Hauske, S. J., Anker, S., Butler, J., Filippatos, G., Packer, M., Zannad, F., Steubl, D., Brueckmann, M., Green, J. B., Emberson, J. R., Landray, M. J., Baigent, C., Haynes, R., & Staplin, N. (2025). Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(25)00222-0

Source records

crossref · retrieved 2026-09-27T06:00:36.290Z